Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

(2013) Ralf Gold et al.   LANCET

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

(2012) Virginia Devonshire et al.   LANCET NEUROLOGY

Daclizumab Therapy for Multiple Sclerosis

(2012) Bibiana Bielekova   Neurotherapeutics

Inhibition of LTi Cell Development by CD25 Blockade Is Associated with Decreased Intrathecal Inflammation in Multiple Sclerosis

(2012) J. S. A. Perry et al.   Science Translational Medicine

Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing–remitting multiple sclerosis

(2011) Roland Martin   CLINICAL IMMUNOLOGY

The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability

(2010) Antonio Scalfari et al.   BRAIN

An IL-2 Paradox: Blocking CD25 on T Cells Induces IL-2-Driven Activation of CD56bright NK Cells

(2010) J. F. Martin et al.   JOURNAL OF IMMUNOLOGY

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

(2010) Daniel Wynn et al.   LANCET NEUROLOGY

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

(2009) M. Hutchinson et al.   JOURNAL OF NEUROLOGY